Indivior ( (INDV) ) just unveiled an announcement.
On August 1, 2026, Indivior and Artemis Merger Sub entered into a merger agreement with Supernus under which Merger Sub will be folded into Supernus, leaving Supernus as a wholly owned subsidiary of Indivior and creating a combined company renamed Supernus, Inc. At closing, each Supernus share will be exchanged for 1.5401 Indivior shares, equity awards will roll into Indivior instruments, and existing Indivior holders are expected to own about 56.5% of the new entity while Supernus investors will hold roughly 43.5%.
Ahead of completion, Indivior will fund a $1 billion special dividend, supported in part by a $650 million committed term loan from Citibank, and the combined board will be evenly split between Indivior and Supernus nominees with Jack A. Khattar as CEO and Timothy C. Dec as CFO. The deal is subject to customary shareholder, regulatory and Nasdaq listing approvals as well as detailed covenants, break fees and voting agreements designed to secure stockholder support, underscoring the strategic importance and negotiated protections surrounding the transaction.
The most recent analyst rating on (INDV) stock is a Buy
with a $46.00 price target.
To see the full list of analyst forecasts on Indivior stock,
see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Outperform.
Overall score reflects strong earnings-call momentum (raised guidance, sharply higher EBITDA outlook, expected positive operating cash flow) and bullish technical trend. These positives are tempered by financial statement risks—especially negative equity and currently negative TTM operating/free cash flow—while valuation appears moderately attractive on a ~10.7 P/E.
To see Spark’s full report on INDV stock,
click here.
More about Indivior
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. are U.S.-based specialty drugmakers focused on prescription pharmaceuticals. Following their agreed merger, Indivior will adopt the Supernus, Inc. name, and the combined company’s shares are expected to trade on Nasdaq under the ticker SUPN, reflecting a unified market presence in specialty therapeutics.
Average Trading Volume: 1,865,985
Technical Sentiment Signal: Buy
Current Market Cap: $4.88B
Learn more about INDV stock on TipRanks’ Stock Analysis page.
Trending Articles:
This story was written using TipRanks's AI tools and reviewed by a TipRanks editor.